Cytox VariaTect SNP Array

Cytox has launched its VariaTect genetic biomarker test for assessing Alzheimer's disease risk. The array, developed for research use, offers a simple blood-based test that provides a comprehensive panel of AD-informative SNPs to assist in research and novel drug discovery studies. It uses a combination of whole exome association analysis, variants identified through genome wide association studies, and variants considered to be of importance in AD-associated biological pathways. This includes approximately 130,000 novel and known SNP variants in gene pathways implicated in AD aetiology. The test was developed in partnership with Thermo Fisher Scientific subsidiary Affymetrix, and will be marketed as the Axiom Dementia Research array.